GlassScriptPhysician profile
Sahar B Hachem
NPI 1942441357
$5,400.07
in general payments reported to CMS, 2019-2025
30 companies · $906 in 2025
The $906 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $605 · 2021: $968 · 2022: $786 · 2023: $734 · 2024: $876 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $973.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $704.36 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $614.49 | 2021-2025 | Freestyle Libre 3, Afinion 2, Freestyle Libre 2 |
| Lilly USA, LLC | $486.27 | 2019-2024 | Mounjaro, Zepbound, Humulin |
| Amgen INC. | $454.33 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbvie INC. | $311.10 | 2019-2024 | |
| Insulet Corporation | $306.68 | 2024-2025 | Omnipod |
| Medtronic, INC. | $212.17 | 2021-2025 | Intellis Adaptivestim, Minimed 780g |
| Astellas Pharma US INC | $192.72 | 2023-2025 | Veozah |
| Medtronic Minimed, INC. | $174.86 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $104.84 | 2021-2023 | Recorlev |
| Corcept Therapeutics | $90.66 | 2022-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $85.40 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $83.80 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $76.53 | 2021-2024 | Farxiga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $74.67 | 2019-2021 | |
| Cequr Corporation | $70.83 | 2024 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $65.14 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.13 | 2021-2024 | Jardiance |
| Radius Health, INC. | $49.94 | 2019-2023 | Tymlos |
| Esperion Therapeutics, INC. | $35.44 | 2021 | |
| Horizon Therapeutics Plc | $33.69 | 2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $33.25 | 2022 | |
| Ibsa Pharma INC. | $24.27 | 2025 | Tirosint, Flector, Licart |
| Averitas Pharma INC. | $22.94 | 2023 | Qutenza |
| Regeneron Healthcare Solutions, INC. | $16.11 | 2019 | |
| Strongbridge US INC. | $14.63 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.19 | 2020 | |
| Amneal Pharmaceuticals LLC | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahar Hachem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.